Source ID: D15
Original URL: https://www.gilead.com/news/news-details/2026/gilead-to-acquire-tubulis-adding-potentially-best-in-class-antibody-drug-conjugate-and-next-generation-platform-to-further-strengthen-oncology-pipeline
Title (supplied): Gilead to Acquire Tubulis
Source date (retained): 2026-04-07
Data date (retained): 2026-04-07
Checked at: 2026-10-07T18:42:41+08:00
Timezone: Asia/Taipei
Checked-at meaning: current review of returned public web-tool extraction; not the historical network-fetch timestamp.
Retrieval mode: public_web_tool_readback_prior_ref; prior saved web_ref was opened and returned the specified original public URL.
Prior web ref: turn17view0
Current web ref: turn120view0
Read level: relevant primary-source paragraphs in web text extraction; complete original HTML/PDF bytes not saved or hashed.
Original network read time: null; not exposed by the tool. Original artifact SHA256: null.
Locator: Acquisition agreement announcement; retrieved lines 304–314 and 319. Agreement, planned organizational integration and terms are at 304, 311 and 314.
Minimum verbatim excerpts (aggregate <=25 English words):
- payable at closing
- up to $1.85 billion in contingent milestone payments
Excerpt word count: 11
Factual extraction (values, dates, statuses; not additional prose quotations):
[
  {
    "field": "closing_cash_consideration",
    "original_value": 3.15,
    "unit_or_role": "USD billion; cash-free/debt-free, customary adjustments, payable at closing",
    "locator": "L314"
  },
  {
    "field": "conditional_milestone_cap",
    "original_value": 1.85,
    "unit_or_role": "USD billion",
    "locator": "L314"
  },
  {
    "field": "expected_closing",
    "original_value": "second quarter of 2026",
    "unit_or_role": "company expectation as of original announcement",
    "locator": "L314"
  },
  {
    "field": "announcement_call_date_text",
    "original_value": "Tuesday, April 7",
    "unit_or_role": "calendar wording returned in body; year from supplied source metadata/URL, not a newly returned date header",
    "locator": "L319"
  }
]
Support scope: Supports signed agreement for all Tubulis equity and promised closing consideration plus conditional milestones; not the subsequent completion or SEC purchase-accounting figures, which remain attributed to D16/D17 in the original row.
Precise gap: The returned extraction did not expose a separate publication date header. Source/data date 2026-04-07 is retained verbatim from the supplied attachment, not relabeled as newly confirmed by a header. Completion and net acquired-cash amounts require the already-cited D16/D17 and are not supported by this pre-close announcement alone.
Source/data dates are supplied baseline metadata, not replaced by this check time. No alternate route, login, headers, private endpoint or payment used.
This small evidence record is an excerpt/factual extraction, not a saved full article.